Use of or codelivery of adjuvants that promote alternative CD4+ T cell fates such as Tfh and germinal center formation, with GLA-SE or A-910823, could enhance formation of tertiary lymphoid structures, which are highly associated with improved therapeutic benefit of cancer vaccines (32–34). This evidence concerns the gene CD4 and cancer.